Latest news with #RituBaral
Business Insider
19-05-2025
- Business
- Business Insider
TD Cowen Reaffirms Their Hold Rating on Spero Therapeutics (SPRO)
TD Cowen analyst Ritu Baral maintained a Hold rating on Spero Therapeutics (SPRO – Research Report) yesterday. The company's shares closed last Friday at $0.65. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Baral is a 3-star analyst with an average return of 2.5% and a 39.31% success rate. Baral covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Alnylam Pharma, and Madrigal Pharmaceuticals. The word on The Street in general, suggests a Hold analyst consensus rating for Spero Therapeutics. SPRO market cap is currently $36.4M and has a P/E ratio of -0.51.
Business Insider
19-05-2025
- Business
- Business Insider
TD Cowen Sticks to Their Hold Rating for Milestone Pharmaceuticals (MIST)
TD Cowen analyst Ritu Baral maintained a Hold rating on Milestone Pharmaceuticals (MIST – Research Report) yesterday. The company's shares closed last Friday at $1.22. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Baral is a 3-star analyst with an average return of 2.5% and a 39.31% success rate. Baral covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Alnylam Pharma, and Madrigal Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Milestone Pharmaceuticals with a $7.50 average price target. MIST market cap is currently $65.23M and has a P/E ratio of -1.47.
